Dendreon Corporation (NASDAQ:DNDN) Announces Results From Provegne Study

981

Dallas, Texas 01/31/2014 (FINANCIALSTRENDS) – The $445 million market capped development stage biotech firm Dendreon Corporation (NASDAQ:DNDN) has announced on 30th January that it has presented the results from the clinical study of its investigational drug designed to achieve “cellular immunotherapy”. The investigated drug combines the two drugs Provegne ( Sipuleucel-T) and another drug code named DN24-02 for treatment of cancer related ailments. The results were presented at the ongoing “2014 Genitourinary Cancers Symposium” in San Francisco.

Commenting about the importance of this development in the overall efforts to develop a viable cancer drug by Dendreon Corporation (NASDAQ:DNDN), its chief medical officer and executive vice president Andrew S. Sandler, M.D has been quoted to have said that, “The PROVENGE and DN24-02 research presented at this year’s ASCO GU Symposium demonstrate Dendreon’s ongoing commitment to our immuno-oncology franchise and patients in need of new and innovative treatment options for cancer. These data further elucidate the mechanism underlying the PROVENGE treatment effect and further our understanding of the role of immunotherapy in cancer treatment.”

On the back of this positive development, the stock posted a 1.43 percent increase in its market value to end the day trading on 30th January at $2.83 per share. This was 27 percent above its 52 week low price point and 60.8 percent below its 52 week high price point.

The data derived from the investigations into using Provegne to treat cancer, indicate that the treatment may lead to development of a “humoral antigen spread” state in the target cells. This spread, Dendreon Corporation (NASDAQ:DNDN) explained, has been established to be linked to improved survival rates of the impacted cells in question. Hence the findings of these phase 3 tests are expected to add more understanding of the various properties exhibited by  sipuleucel-T and how these actions can help the researchers identify the post treatment “biomarkers” which can be used for later stage clinical trials.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.